Evicenter
P&T meetings

Tovorafenib (DAY101)

RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

Also known as TAK-580
Regulatory submission
Not announced
Launch
Not announced
Last updated
155 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

Economic impact of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy on families

23 evidence topics · 7 sources

Summary: family financial burden and parental work loss

No study was identified that measures family financial burden specifically in pLGG. Evidence from pediatric brain tumors and pediatric cancer overall indicates the following. At a U.S. cancer center, 16% of 202 patients younger than 21 years who underwent neurosurgery for a cancer-related diagnosis had financial toxicity before surgery, and the 2-year cumulative incidence after surgery was 19%; among 86 patients who survived at least 2 years, 34% experienced financial toxicity, and most affected patients had commercial insurance. In a U.S. single-site survey of 254 caregivers of children with cancer, approximately one third reported that a parent quit or changed work because of the child's cancer, and this was associated with a 13.4-point higher financial burden score (0 to 100 scale) at 1 to 5 years after diagnosis. A systematic review of 35 studies reported frequent parental job loss or job quitting, particularly among mothers, with effects persisting into early survivorship. In a Canadian cohort of 28 families, median first-year indirect costs were $9,668 and median income loss was 55 days. In the Childhood Cancer Survivor Study (3,023 adult survivors; 16% with CNS tumors), survivors with 4 impaired neurocognitive domains had odds ratios of 3.12 for debt collection and 3.77 for bankruptcy compared with survivors with no impaired domains.

Out-of-pocket costs and parental work loss specific to pLGG or to oral MAPK inhibitor versus intravenous chemotherapy

No evidence found.